FDA Approves Subcutaneous Opdivo Qvantig for Most Solid Tumor Indications
By Lori Solomon HealthDay Reporter
FRIDAY, Jan. 3, 2025 -- The U.S. Food and Drug Administration has approved Opdivo Qvantig (nivolumab and hyaluronidase-nvhy) injection for subcutaneous use for most previously approved adult, solid tumor Opdivo (nivolumab) indications.
Opdivo Qvantig is a combination product of nivolumab coformulated with recombinant human hyaluronidase. This approval is for most previously approved adult, solid tumor Opdivo indications as monotherapy, monotherapy maintenance following completion of Opdivo plus Yervoy (ipilimumab) combination therapy, or in combination with chemotherapy or cabozantinib.
The approval is based on results from the phase 3 randomized, open-label CheckMate-67T trial, which demonstrated noninferiority for the coprimary end points of time-averaged concentration over 28 days and minimum concentration at a steady state of Opdivo Qvantig versus intravenous Opdivo. Additionally, the trial showed an overall response rate for Opdivo Qvantig of 24 percent versus 18 percent in the intravenous Opdivo arm.
"Over the last decade, Opdivo has evolved as an immunotherapy option used in many indications across tumor types," Adam Lenkowsky, executive vice president and chief commercialization officer at Bristol Myers Squibb, said in a statement. "With this new option, we look forward to further helping cancer patients with an administration method that gives them faster delivery."
Approval of subcutaneous Opdivo Qvantig was granted to Bristol Myers Squibb.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted January 2025
Read this next
DDW: Systematic Program Increases Likelihood of Up-to-Date Colorectal Cancer Screening
FRIDAY, April 25, 2025 -- A systematic program of monitoring colorectal cancer (CRC) screening status increases up-to-date screening status, according to a study presented at the...
Prevalence of Most Cancer Risk Factors Unchanged Before, After Pandemic
THURSDAY, April 24, 2025 -- Smoking rates continued to decline during the COVID-19 pandemic, but other major risk factors for cancer remained stable, according to a study...
2000 to 2021 Saw Increase in Incidence of Pancreatic Adenocarcinoma
WEDNESDAY, April 23, 2025 -- From 2000 to 2021, there was an increase in the incidence of pancreatic adenocarcinoma, which was seen in all age groups, according to a study...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.